Project Grant R21AI196582
Award Date 9/3/26
Completion Date 8/31/28
Dollars Obligated $484K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded New York University $254,250 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to test the epigenetic basis and evolutionary generality of bacterial persistence in Staphylococcus aureus. The research examines how bacteria survive antibiotic treatment without genetic changes—a phenomenon distinct from drug resistance and drug tolerance. The project builds on preliminary findings that...
- The National Institute of Allergy and Infectious Diseases awarded Trustees of Tufts College (doing business as Tufts University School of Medicine) $151,040 on January 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify and characterize the unique cell division machinery of Clostridioides difficile, a major nosocomial pathogen. The research addresses a critical gap in understanding bacterial cell division. Unlike model organisms studied over decades,...
- The National Institute of Allergy and Infectious Diseases awarded Trustees of Tufts College (doing business as Tufts University School of Medicine) $315,700 on January 29, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research elucidating spatio-temporal innate immune cell modulation of Mycobacterium tuberculosis stress response and replication heterogeneity. The project investigates how spatial organization of tuberculosis lesions in the lung...
- The National Institute of Allergy and Infectious Diseases awarded Beth Israel Deaconess Medical Center, Inc. $844,925 on August 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to design apramycin analogs targeting resistance in gram-negative pathogens. The project focuses on structure-guided derivatization of apramycin to block inactivation by aminoglycoside-modifying enzymes and extend activity spectrum to multidrug-resistant gram-negative ESKAPE...
- The National Institute of Allergy and Infectious Diseases awarded $182,424 to Trustees of Tufts College (doing business as Tufts University School of Medicine) on October 24, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research on the effect of epithelium association and toxin gene expression on Clostridioides difficile disease severity. The research addresses the mechanisms driving disease severity in C. difficile infection (CDI), the most common...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services, awarded $148,614 to Massachusetts Institute of Technology on January 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The recipient will develop glycopolymers designed to enhance interactions between immune cells and pathogenic bacteria, creating "cellular glues" that leverage the body's innate immune mechanisms as an alternative to...
- The National Institute of Allergy and Infectious Diseases awarded Emory University $161,244 on April 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct experimental evolution assays elucidating evolutionary trajectories to antibiotic resistance in Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli, and how the immune system modifies these trajectories. The research uses in vivo adaptive laboratory evolution experiments in Galleria...
- The National Institute of Allergy and Infectious Diseases awarded Beth Israel Deaconess Medical Center, Inc. $987,730 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop next-generation spectinomycin analogs that evade adenylase-based resistance mechanisms and demonstrate enhanced potency against multidrug-resistant gram-negative pathogens including carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii. The...
- The National Institute of Allergy and Infectious Diseases awarded Northeastern University $650,221 on June 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop an efficient platform for antibiotic discovery by culturing and mining uncultured bacteria. The project, titled "An Efficient Platform for Antibiotic Discovery," addresses the challenge that the vast majority of bacteria on the planet do not grow in laboratory conditions. The recipient...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $795,313 on August 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on subcellular definition of accumulation in Escherichia coli as a strategy to address antimicrobial resistance. The research seeks to formulate foundational principles governing molecular characteristics that define cellular penetration in bacteria, similar to Lipinski's Rule of Five...